



**Contacts:**

Doug Doerfler  
President & CEO  
MaxCyte, Inc  
(301) 944-1700  
[dougd@maxcyte.com](mailto:dougd@maxcyte.com)

Carolyn Hawley  
Atkins + Associates  
Media & Investor Relations, MaxCyte  
(858) 527-3484  
[chawley@irpr.com](mailto:chawley@irpr.com)

**MAXCYTE AWARDED FUNDAMENTAL U.S. PATENT COVERING ELECTROPORATION USING COMPUTER CONTROL**

Gaithersburg, MD – January 18, 2005 – MaxCyte, Inc., a biotechnology company developing cell-based therapeutics and technologies, announced today that it was awarded U.S. Patent No. 6,773,669 entitled "Flow Electroporation Chamber and Method" from the U.S. Patent and Trademark Office. This patent broadly covers any electroporation system that incorporates a computer to control, for example, the flow of biological materials through the electroporation chamber as well as other aspects of electroporation, such as electrical pulsing parameters. The '669 patent complements and expands MaxCyte's intellectual property position in the United States, Europe and other countries, which includes claims to various electroporation system designs and processes as well as the company's unique flow-based technology.

Electroporation – using electric current to make cell membranes permeable to allow the introduction of new DNA or other molecules – is a technology that, in its static form, has been used in research settings for decades. By loading cells in a flow process and automating the system by computer, MaxCyte has refined electroporation in order to vastly increase the volume, efficiency and viability of cells loaded so that the technology can be used for rapidly developing cell-based therapeutics and biotherapeutic manufacturing.

MaxCyte's closed and sterile clinical grade system is amenable to multiple applications, introducing nucleic acids (genes, siRNA), drugs or proteins to any cell type, and the highly reproducible process achieves efficiencies and cell viabilities unmatched by any other cell loading method. Therapeutic applications include *ex vivo* gene delivery and delivery of therapeutic small molecules or large proteins. The MaxCyte system is currently being used in a Phase I/II clinical trial of a proprietary immunotherapeutic for chronic lymphocytic leukemia at the Baylor College of Medicine. MaxCyte's partners are also working to develop drugs for cardiopulmonary disease, infectious diseases and oncology. For biotherapeutic manufacturing, applications of MaxCyte's system include the scalable production of viral vectors, making possible all phases of the biotherapeutic development process, from pre-clinical through clinical trials and through to product commercialization.

"This patent adds considerably to MaxCyte's growing intellectual property portfolio and represents a broad and very commercially relevant patent. Securing claims covering our unique electroporation technology reduces risk related to development of novel cell-based therapeutics and biotherapeutic manufacturing. This is particularly attractive to our partners who are utilizing our cell loading technology to advance their drug programs," stated Doug Doerfler, president and CEO of MaxCyte, Inc.

**About MaxCyte**

MaxCyte, Inc. is a clinical stage company developing both proprietary and partnered therapeutics. A pioneer in the design of clinical grade, non-viral cell loading and gene delivery systems, MaxCyte's proprietary technology breaks down the barriers to clinical *ex vivo* cell loading and biotherapeutic manufacturing, including the scalable production of viral vectors, which are critical to developing gene therapies. The company's pipeline includes an immunotherapeutic for chronic lymphocytic leukemia in Phase I/II clinical trials and several preclinical candidates to address unmet medical needs, primarily in oncology. Collaborators are taking advantage of MaxCyte's customizable approach to accelerate drug development programs for cardiopulmonary disease, infectious diseases and oncology. For more information, visit [www.maxcyte.com](http://www.maxcyte.com).

###